VERU INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
VERU INC. (VERU) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$325.96 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.03M, a 42.53% increase year-over-year.
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.30M.
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $942.21K.
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $514.88K, a 56.40% decline year-over-year.
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.35M, a 134.16% decline from fiscal 2024.
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $3.94M.
- VERU INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$11.72M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | -$1.27M derived: sum of 2 quarters · filed 2026-08-10 | -$325.96K 10-Q · filed 2026-08-10 | $188.91K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$1.36M 10-Q · filed 2026-05-13 | -$843.01K derived: sum of 3 quarters · filed 2026-05-13 | -$119.02K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $942.21K 10-Q · filed 2026-02-11 | $1.46M derived: sum of 2 quarters · filed 2026-02-11 | $2.18M derived: sum of 3 quarters · filed 2026-08-10 | $1.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-09-30 | $514.88K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $1.24M derived: sum of 2 quarters · filed 2026-08-10 | $295.74K derived: sum of 3 quarters · filed 2026-08-10 | -$1.35M 10-K · filed 2025-12-17 |
| 2025-06-30 | $724.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | -$219.14K derived: sum of 2 quarters · filed 2026-08-10 | -$1.86M 10-Q · filed 2026-08-10 | -$681.59K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$943.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$2.59M 10-Q · filed 2026-05-13 | -$1.41M derived: sum of 3 quarters · filed 2026-05-13 | -$875.27K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$1.64M 10-Q · filed 2026-02-11 | -$462.45K derived: sum of 2 quarters · filed 2026-02-11 | $67.87K derived: sum of 3 quarters · filed 2026-02-11 | $1.01M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $1.71M derived: sum of 2 quarters · filed 2025-12-17 | $2.65M derived: sum of 3 quarters · filed 2025-12-17 | $3.94M 10-K · filed 2025-12-17 |
| 2024-06-30 | $530.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $1.47M derived: sum of 2 quarters · filed 2025-08-12 | $2.76M 10-Q · filed 2025-08-12 | -$2.25M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $937.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-08 | $2.23M 10-Q · filed 2025-05-08 | -$2.78M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.30M 10-Q · filed 2025-02-13 | -$3.71M derived: sum of 2 quarters · filed 2025-02-13 | ||
| 2023-09-30 | -$5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | -$11.72M 10-K · filed 2024-12-16 | ||
| 2023-06-30 | -$6.71M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |